02 · Competitive Preference

Visibility does not necessarily translate into preference.

The therapies AI names most are not the ones it favours most in head-to-head questions.

Comparisons differ by opponent and question type. Equal and conditional verdicts are shown, not discarded.

Six therapies, in visibility order

2Abatacept38%
3Rituximab35%
4Tocilizumab28%
5Tofacitinib23%
6Adalimumab21%
7Upadacitinib20%

FavouredEqual · Conditional · OtherComparator favoured

See each therapy in the therapy lens

Head-to-head explorer

Compare two therapies, as AI compares them.

Choose any two therapies compared at least 8 times. A pair compared fewer times, or never, is not offered, and is not zero.

AdalimumabvsUpadacitinib

32 answers · 8 questionsOne answer per question from each of the four AI systems.

0Adalimumab favoured

23Upadacitinib favoured

823

Equal8
Conditional1
Other0

Featured comparison

Upadacitinib is 7th for visibility, yet AI favours it over adalimumab in 23 of 32 head-to-head answers; adalimumab is favoured in none. 8 answers are judged equal, all on cardiovascular or infection questions, and 1 is conditional.

The same split holds in each of the four AI systems: adalimumab is favoured in none of each system's 8 answers.

SELECT-COMPARE is the head-to-head trial the AI answers cite. This describes AI answers, not a clinical recommendation.

By question type

Efficacy & speed8 answersSmall base
Adalimumab favoured 0Equal 0Conditional 0Other 0Upadacitinib favoured 8
Convenience & administration4 answersSmall base
Adalimumab favoured 0Equal 0Conditional 0Other 0Upadacitinib favoured 4
Persistence & adherence8 answersSmall base
Adalimumab favoured 0Equal 0Conditional 1Other 0Upadacitinib favoured 7
Infection & zoster4 answersSmall base
Adalimumab favoured 0Equal 4Conditional 0Other 0Upadacitinib favoured 0
CV / VTE risk4 answersSmall base
Adalimumab favoured 0Equal 4Conditional 0Other 0Upadacitinib favoured 0
Positioning, profiles & other4 answersSmall base
Adalimumab favoured 0Equal 0Conditional 0Other 0Upadacitinib favoured 4

How to read a verdict

Favoured: The AI judge scored the therapy "preferred" and its comparator "inferior", with no judge-noted condition. This is the only outcome described as "favoured".
Equal: Both scored "equal" (parity).
Conditional: A win (two-sided preferred/inferior, or one-sided preferred/inferior) whose judge reasoning makes the choice depend on patient or clinical context (judge-noted conditional), or a mixed verdict (both preferred or both inferior). Never counted as favoured.
Other: Only one therapy was scored, no clear preference was expressed, or one therapy was not mentioned. Never counted as favoured.
Comparator favoured: The comparator was cleanly favoured.

“Small base” marks a figure resting on fewer than 10 answers. Many question-type rows rest on 4: one question, answered once by each AI system.

Every pair compared at least 8 times (42)

Each filled cell is a pair and its number of answers. An empty cell was compared fewer than 8 times, or not at all.

	Methotrexate	Abatacept	Rituximab	Tocilizumab	Tofacitinib	Adalimumab	Upadacitinib	Baricitinib	Etanercept	Sulfasalazine	Infliximab	Leflunomide	Sarilumab	Certolizumab pegol
Abatacept
Rituximab		28
Tocilizumab		28	12
Tofacitinib		12	8	8
Adalimumab		32		24	20
Upadacitinib		24	12	12	24	32
Baricitinib		8	8	8	20	24	20
Etanercept		8		12	24	24	8	8
Sulfasalazine	8
Infliximab				8		8
Leflunomide	8
Sarilumab		12	8	28	8	20	8	8
Certolizumab pegol						20	8		12
Golimumab				8		8

View every comparison as a table

Pair	Question type	Answers	A favoured	B favoured	Equal	Conditional	Other
Abatacept (A) · Adalimumab (B)	All questions	32	7	1	10	9	5
	Efficacy & speed	4	0	0	4	0	0
	Convenience & administration	4	0	0	0	0	4
	Persistence & adherence	4	3	0	0	1	0
	Infection & zoster	8	2	0	1	5	0
	Positioning, profiles & other	12	2	1	5	3	1
Adalimumab (A) · Upadacitinib (B)	All questions	32	0	23	8	1	0
	Efficacy & speed	8	0	8	0	0	0
	Convenience & administration	4	0	4	0	0	0
	Persistence & adherence	8	0	7	0	1	0
	Infection & zoster	4	0	0	4	0	0
	CV / VTE risk	4	0	0	4	0	0
	Positioning, profiles & other	4	0	4	0	0	0
Abatacept (A) · Rituximab (B)	All questions	28	6	2	8	5	7
	Efficacy & speed	4	0	1	3	0	0
	Convenience & administration	4	0	0	0	0	4
	Infection & zoster	8	5	0	1	2	0
	Positioning, profiles & other	12	1	1	4	3	3
Abatacept (A) · Tocilizumab (B)	All questions	28	5	6	7	2	8
	Efficacy & speed	4	0	1	2	0	1
	Convenience & administration	4	0	0	0	0	4
	Persistence & adherence	4	0	1	2	1	0
	Infection & zoster	4	4	0	0	0	0
	Positioning, profiles & other	12	1	4	3	1	3
Sarilumab (A) · Tocilizumab (B)	All questions	28	0	4	14	0	10
	Efficacy & speed	8	0	1	6	0	1
	Convenience & administration	4	0	0	0	0	4
	Positioning, profiles & other	16	0	3	8	0	5
Abatacept (A) · Upadacitinib (B)	All questions	24	5	11	0	5	3
	Efficacy & speed	4	0	4	0	0	0
	Convenience & administration	4	0	4	0	0	0
	Infection & zoster	8	3	0	0	4	1
	CV / VTE risk	4	2	0	0	1	1
	Positioning, profiles & other	4	0	3	0	0	1
Adalimumab (A) · Baricitinib (B)	All questions	24	3	13	4	3	1
	Efficacy & speed	8	0	8	0	0	0
	Convenience & administration	4	0	3	1	0	0
	Infection & zoster	4	1	0	3	0	0
	CV / VTE risk	4	2	0	0	2	0
	Positioning, profiles & other	4	0	2	0	1	1
Adalimumab (A) · Etanercept (B)	All questions	24	4	6	11	1	2
	Efficacy & speed	4	1	0	3	0	0
	Convenience & administration	4	2	1	1	0	0
	Persistence & adherence	4	0	1	3	0	0
	Positioning, profiles & other	12	1	4	4	1	2
Adalimumab (A) · Tocilizumab (B)	All questions	24	0	11	5	3	5
	Efficacy & speed	4	0	3	0	1	0
	Convenience & administration	4	0	0	0	0	4
	Persistence & adherence	4	0	4	0	0	0
	Infection & zoster	4	0	0	4	0	0
	Positioning, profiles & other	8	0	4	1	2	1
Etanercept (A) · Tofacitinib (B)	All questions	24	8	3	10	0	3
	Efficacy & speed	4	0	0	4	0	0
	Convenience & administration	4	0	3	0	0	1
	Persistence & adherence	4	0	0	4	0	0
	Infection & zoster	4	3	0	0	0	1
	CV / VTE risk	4	3	0	0	0	1
	Positioning, profiles & other	4	2	0	2	0	0
Tofacitinib (A) · Upadacitinib (B)	All questions	24	0	11	3	2	8
	Efficacy & speed	4	0	4	0	0	0
	Convenience & administration	4	0	0	0	0	4
	Persistence & adherence	4	0	3	0	1	0
	Infection & zoster	4	0	0	2	0	2
	CV / VTE risk	4	0	1	1	0	2
	Positioning, profiles & other	4	0	3	0	1	0
Adalimumab (A) · Certolizumab pegol (B)	All questions	20	1	5	11	1	2
	Efficacy & speed	4	0	0	4	0	0
	Convenience & administration	4	1	1	1	1	0
	Positioning, profiles & other	12	0	4	6	0	2
Adalimumab (A) · Sarilumab (B)	All questions	20	0	10	4	1	5
	Efficacy & speed	4	0	4	0	0	0
	Convenience & administration	4	0	0	0	0	4
	Infection & zoster	4	0	1	3	0	0
	Positioning, profiles & other	8	0	5	1	1	1
Adalimumab (A) · Tofacitinib (B)	All questions	20	3	4	6	5	2
	Efficacy & speed	4	0	0	3	0	1
	Convenience & administration	4	0	4	0	0	0
	Infection & zoster	4	0	0	2	1	1
	CV / VTE risk	4	2	0	0	2	0
	Positioning, profiles & other	4	1	0	1	2	0
Baricitinib (A) · Tofacitinib (B)	All questions	20	2	0	8	0	10
	Efficacy & speed	4	1	0	2	0	1
	Convenience & administration	4	0	0	0	0	4
	Infection & zoster	4	0	0	4	0	0
	CV / VTE risk	4	0	0	1	0	3
	Positioning, profiles & other	4	1	0	1	0	2
Baricitinib (A) · Upadacitinib (B)	All questions	20	0	6	7	0	7
	Efficacy & speed	4	0	3	1	0	0
	Convenience & administration	4	0	0	1	0	3
	Infection & zoster	4	0	0	2	0	2
	CV / VTE risk	4	0	1	1	0	2
	Positioning, profiles & other	4	0	2	2	0	0
Abatacept (A) · Sarilumab (B)	All questions	12	6	0	2	0	4
	Efficacy & speed	8	3	0	1	0	4
	Infection & zoster	4	3	0	1	0	0
Abatacept (A) · Tofacitinib (B)	All questions	12	5	0	5	2	0
	Efficacy & speed	4	0	0	4	0	0
	CV / VTE risk	4	2	0	0	2	0
	Positioning, profiles & other	4	3	0	1	0	0
Certolizumab pegol (A) · Etanercept (B)	All questions	12	2	4	3	3	0
	Efficacy & speed	4	0	1	3	0	0
	Positioning, profiles & other	8	2	3	0	3	0
Etanercept (A) · Tocilizumab (B)	All questions	12	0	5	7	0	0
	Efficacy & speed	4	0	1	3	0	0
	CV / VTE risk	4	0	0	4	0	0
	Positioning, profiles & other	4	0	4	0	0	0
Rituximab (A) · Tocilizumab (B)	All questions	12	1	2	3	3	3
	Infection & zoster	4	0	2	2	0	0
	Positioning, profiles & other	8	1	0	1	3	3
Rituximab (A) · Upadacitinib (B)	All questions	12	0	0	4	5	3
	Infection & zoster	4	0	0	0	2	2
	Positioning, profiles & other	8	0	0	4	3	1
Tocilizumab (A) · Upadacitinib (B)	All questions	12	3	0	4	2	3
	Efficacy & speed	4	0	0	3	0	1
	CV / VTE risk	4	2	0	0	1	1
	Positioning, profiles & other	4	1	0	1	1	1
Abatacept (A) · Baricitinib (B)	All questions	8	2	3	1	2	0
	Efficacy & speed	4	0	3	1	0	0
	CV / VTE risk	4	2	0	0	2	0
Abatacept (A) · Etanercept (B)	All questions	8	0	2	4	1	1
	Efficacy & speed	4	0	0	4	0	0
	Positioning, profiles & other	4	0	2	0	1	1
Adalimumab (A) · Golimumab (B)	All questions	8	0	3	5	0	0
	Efficacy & speed	4	0	0	4	0	0
	Positioning, profiles & other	4	0	3	1	0	0
Adalimumab (A) · Infliximab (B)	All questions	8	2	0	6	0	0
	Efficacy & speed	4	1	0	3	0	0
	Positioning, profiles & other	4	1	0	3	0	0
Baricitinib (A) · Etanercept (B)	All questions	8	1	3	2	1	1
	Efficacy & speed	4	1	0	2	0	1
	CV / VTE risk	4	0	3	0	1	0
Baricitinib (A) · Rituximab (B)	All questions	8	0	1	4	3	0
	Infection & zoster	4	0	1	2	1	0
	Positioning, profiles & other	4	0	0	2	2	0
Baricitinib (A) · Sarilumab (B)	All questions	8	1	2	2	3	0
	Efficacy & speed	4	1	0	2	1	0
	CV / VTE risk	4	0	2	0	2	0
Baricitinib (A) · Tocilizumab (B)	All questions	8	1	5	0	1	1
	Efficacy & speed	4	1	2	0	0	1
	CV / VTE risk	4	0	3	0	1	0
Certolizumab pegol (A) · Upadacitinib (B)	All questions	8	1	3	1	1	2
	Efficacy & speed	4	0	3	1	0	0
	CV / VTE risk	4	1	0	0	1	2
Etanercept (A) · Upadacitinib (B)	All questions	8	1	3	0	3	1
	Efficacy & speed	4	0	3	0	0	1
	CV / VTE risk	4	1	0	0	3	0
Golimumab (A) · Tocilizumab (B)	All questions	8	0	5	0	2	1
	Efficacy & speed	4	0	2	0	1	1
	Positioning, profiles & other	4	0	3	0	1	0
Infliximab (A) · Tocilizumab (B)	All questions	8	0	6	1	1	0
	Efficacy & speed	4	0	2	1	1	0
	Positioning, profiles & other	4	0	4	0	0	0
Leflunomide (A) · Methotrexate (B)	All questions	8	0	2	4	0	2
	Efficacy & speed	4	0	1	1	0	2
	Positioning, profiles & other	4	0	1	3	0	0
Methotrexate (A) · Sulfasalazine (B)	All questions	8	7	0	1	0	0
	Efficacy & speed	4	4	0	0	0	0
	Positioning, profiles & other	4	3	0	1	0	0
Rituximab (A) · Sarilumab (B)	All questions	8	2	0	2	1	3
	Infection & zoster	4	1	0	1	0	2
	Positioning, profiles & other	4	1	0	1	1	1
Rituximab (A) · Tofacitinib (B)	All questions	8	4	0	0	1	3
	Infection & zoster	4	2	0	0	0	2
	Positioning, profiles & other	4	2	0	0	1	1
Sarilumab (A) · Tofacitinib (B)	All questions	8	3	0	3	1	1
	Efficacy & speed	4	0	0	3	0	1
	CV / VTE risk	4	3	0	0	1	0
Sarilumab (A) · Upadacitinib (B)	All questions	8	1	0	4	3	0
	Efficacy & speed	4	0	0	3	1	0
	CV / VTE risk	4	1	0	1	2	0
Tocilizumab (A) · Tofacitinib (B)	All questions	8	4	0	2	1	1
	Efficacy & speed	4	1	0	2	0	1
	CV / VTE risk	4	3	0	0	1	0

Discover how AI positions your therapy against your competitors, question by question.

Schedule a meeting

Therapy lens

Visible, first, favoured: one therapy at a time.

Abatacept is the 2nd most visible therapy, but 74 of its 168 head-to-head comparisons (44%) end equal or conditional.

Comparisons differ by opponent and question type. Equal and conditional verdicts are shown, not discarded.

Each therapy's total counts every comparison that names it, including pairs compared fewer than 8 times that the explorer does not offer.

Abatacept

AI Visibility

Is it named at all?

38%

697 of 1,816 answers · rank 2 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

9%

130 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

37 · 22%Favoured

25 · 15%Comparator favoured

374625

Equal46 · 27%
Conditional28 · 17%
Other32 · 19%

168 judgments against 12 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapyFavoured in 1 of 12
After TNF-inhibitor failureFavoured in 3 of 28
Pregnancy planning
Not shown. Compared fewer than 8 times in this profile, or not at all.
Cardiovascular & thromboembolic riskFavoured in 6 of 12

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Abatacept head to head →Follow Abatacept across the patient profiles →

Rituximab

AI Visibility

Is it named at all?

35%

644 of 1,816 answers · rank 3 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

8%

117 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

19 · 20%Favoured

8 · 8%Comparator favoured

1921

Equal21 · 22%
Conditional25 · 26%
Other23 · 24%

96 judgments against 11 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapy
Not shown. Compared fewer than 8 times in this profile, or not at all.
After TNF-inhibitor failureFavoured in 14 of 48
Pregnancy planning
Not shown. Compared fewer than 8 times in this profile, or not at all.
Cardiovascular & thromboembolic risk
Not shown. Compared fewer than 8 times in this profile, or not at all.

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Rituximab head to head →Follow Rituximab across the patient profiles →

Tocilizumab

AI Visibility

Is it named at all?

28%

508 of 1,816 answers · rank 4 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

7%

99 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

59 · 37%Favoured

7 · 4%Comparator favoured

5945

Equal45 · 28%
Conditional15 · 9%
Other34 · 21%

160 judgments against 13 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapyFavoured in 18 of 24
After TNF-inhibitor failureFavoured in 6 of 24
Pregnancy planning
Not shown. Compared fewer than 8 times in this profile, or not at all.
Cardiovascular & thromboembolic riskFavoured in 8 of 16

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Tocilizumab head to head →Follow Tocilizumab across the patient profiles →

Tofacitinib

AI Visibility

Is it named at all?

23%

414 of 1,816 answers · rank 5 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

8%

116 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

11 · 8%Favoured

44 · 31%Comparator favoured

4544

Equal45 · 31%
Conditional13 · 9%
Other31 · 22%

144 judgments against 13 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapy
Not shown. Compared fewer than 8 times in this profile, or not at all.
After TNF-inhibitor failureFavoured in 0 of 32
Pregnancy planning
Not shown. Compared fewer than 8 times in this profile, or not at all.
Cardiovascular & thromboembolic riskFavoured in 0 of 20

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Tofacitinib head to head →Follow Tofacitinib across the patient profiles →

Adalimumab

AI Visibility

Is it named at all?

21%

381 of 1,816 answers · rank 6 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

6%

87 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

16 · 7%Favoured

83 · 38%Comparator favoured

7183

Equal71 · 32%
Conditional26 · 12%
Other24 · 11%

220 judgments against 12 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapyFavoured in 1 of 12
After TNF-inhibitor failure
Not shown. Compared fewer than 8 times in this profile, or not at all.
Pregnancy planningFavoured in 0 of 8Small base
Cardiovascular & thromboembolic riskFavoured in 4 of 12

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Adalimumab head to head →Follow Adalimumab across the patient profiles →

Upadacitinib

AI Visibility

Is it named at all?

20%

363 of 1,816 answers · rank 7 of 25 scored therapies

Named first

When a scored therapy is named, is it this one first?

3%

39 of 1,496 answers naming any scored therapy. Order of mention, not preference.

Head-to-head verdicts

When an answer compares it with another therapy, which does it favour?

65 · 41%Favoured

11 · 7%Comparator favoured

6531

Equal31 · 19%
Conditional23 · 14%
Other30 · 19%

160 judgments against 12 opponents, including pairs compared fewer than 8 times.

Patient profiles

Does the verdict change with the patient?

MTX intolerance / monotherapy
Not shown. Compared fewer than 8 times in this profile, or not at all.
After TNF-inhibitor failureFavoured in 16 of 32
Pregnancy planning
Not shown. Compared fewer than 8 times in this profile, or not at all.
Cardiovascular & thromboembolic riskFavoured in 0 of 24

Each profile has its own questions and comparators. Not a controlled comparison.

Compare Upadacitinib head to head →Follow Upadacitinib across the patient profiles →

Question context

The question changes the verdict.

No JAK inhibitor is clearly favoured in any of 64 cardiovascular or thromboembolic comparisons, in each of the four AI systems.

JAK inhibitors are favoured in 52 of 116 efficacy comparisons and 18 of 20 convenience comparisons, but in none of 36 infection or zoster comparisons.

All AI systems · 292 judgments

Efficacy & speed116 judgments
52 · 45%Equal 39 · Conditional 4 · Other 174 · 3%
Convenience & administration20 judgments
18 · 90%Equal 1 · Conditional 0 · Other 10 · 0%
Persistence & adherence12 judgments
7 · 58%Equal 4 · Conditional 1 · Other 00 · 0%
Infection & zoster36 judgments
0 · 0%Equal 11 · Conditional 8 · Other 710 · 28%
CV / VTE risk64 judgments
0 · 0%Equal 5 · Conditional 22 · Other 532 · 50%
Positioning, profiles & other44 judgments
9 · 20%Equal 11 · Conditional 10 · Other 59 · 20%

ChatGPT · each row shows its own base

Efficacy & speed29 judgments
14 · 48%Equal 11 · Conditional 1 · Other 12 · 7%
Convenience & administration5 judgmentsSmall base
5 · 100%Equal 0 · Conditional 0 · Other 00 · 0%
Persistence & adherence3 judgmentsSmall base
2 · 67%Equal 1 · Conditional 0 · Other 00 · 0%
Infection & zoster9 judgmentsSmall base
0 · 0%Equal 2 · Conditional 2 · Other 14 · 44%
CV / VTE risk16 judgments
0 · 0%Equal 1 · Conditional 6 · Other 09 · 56%
Positioning, profiles & other11 judgments
1 · 9%Equal 2 · Conditional 2 · Other 24 · 36%

Claude · each row shows its own base

Efficacy & speed29 judgments
16 · 55%Equal 5 · Conditional 2 · Other 60 · 0%
Convenience & administration5 judgmentsSmall base
5 · 100%Equal 0 · Conditional 0 · Other 00 · 0%
Persistence & adherence3 judgmentsSmall base
2 · 67%Equal 1 · Conditional 0 · Other 00 · 0%
Infection & zoster9 judgmentsSmall base
0 · 0%Equal 4 · Conditional 1 · Other 04 · 44%
CV / VTE risk16 judgments
0 · 0%Equal 2 · Conditional 5 · Other 27 · 44%
Positioning, profiles & other11 judgments
3 · 27%Equal 2 · Conditional 4 · Other 11 · 9%

Gemini · each row shows its own base

Efficacy & speed29 judgments
9 · 31%Equal 12 · Conditional 0 · Other 80 · 0%
Convenience & administration5 judgmentsSmall base
4 · 80%Equal 0 · Conditional 0 · Other 10 · 0%
Persistence & adherence3 judgmentsSmall base
2 · 67%Equal 1 · Conditional 0 · Other 00 · 0%
Infection & zoster9 judgmentsSmall base
0 · 0%Equal 3 · Conditional 2 · Other 40 · 0%
CV / VTE risk16 judgments
0 · 0%Equal 1 · Conditional 4 · Other 38 · 50%
Positioning, profiles & other11 judgments
3 · 27%Equal 5 · Conditional 0 · Other 21 · 9%

Perplexity · each row shows its own base

Efficacy & speed29 judgments
13 · 45%Equal 11 · Conditional 1 · Other 22 · 7%
Convenience & administration5 judgmentsSmall base
4 · 80%Equal 1 · Conditional 0 · Other 00 · 0%
Persistence & adherence3 judgmentsSmall base
1 · 33%Equal 1 · Conditional 1 · Other 00 · 0%
Infection & zoster9 judgmentsSmall base
0 · 0%Equal 2 · Conditional 3 · Other 22 · 22%
CV / VTE risk16 judgments
0 · 0%Equal 1 · Conditional 7 · Other 08 · 50%
Positioning, profiles & other11 judgments
2 · 18%Equal 2 · Conditional 4 · Other 03 · 27%

Baricitinib, Tofacitinib, Upadacitinib

292 head-to-head judgments in which tofacitinib, baricitinib or upadacitinib is compared with a non-JAK therapy. Includes pairs compared fewer than 8 times that the explorer does not offer.

Describes AI answers to the questions asked. Not a clinical comparison, and not evidence of differential CV risk between JAK inhibitors.

Scientific interpretation

What a verdict is, and what it is not.

An AI judge (gpt-4.1-mini) scored each named therapy in each comparative answer as preferred, equal, inferior or not compared. Pair outcomes were derived from these scores without inference from order, frequency or sentiment. A therapy is "favoured" only when it was preferred, its comparator inferior, and the judge noted no condition. Conditional verdicts are shown separately and never counted as favoured.

Head-to-head verdicts describe AI answers to specific comparative questions, not clinical value. Equal and conditional verdicts are shown, not discarded.

What this means

For brand directors and medical affairs leads

A visibility score cannot show where a therapy is favoured, where it draws and where the verdict is conditional. In this benchmark those outcomes change with the opponent and the question, so competitive messaging has to be read question by question.

What limits this reading

A verdict describes what one AI answer favoured for one question. It is not a clinical comparison, and pooled outcomes do not establish clinical superiority. Many comparisons rest on small bases; each is shown.

The Theralexis capability

Theralexis runs head-to-head comparisons for your therapy against the competitors you name, by question type and AI system, and repeats them.

About this benchmark

What was measured

AI representation analysis of 1,816 answers to US rheumatologist-style open questions and 960 answers to comparative questions from four web-enabled AI systems (ChatGPT, Claude, Gemini, Perplexity), collected 30 October 2026 with a US rheumatologist persona. Visibility = share of answers naming a therapy. Neither visibility, order of mention nor head-to-head verdicts indicate clinical efficacy, safety, preference or recommendation.

Pre-ACR baseline (v1.1 corrected analytical view, 30 Oct 2026). Re-measured after ACR Convergence 2026.

Full methodology

Sources and scope

Publisher: Theralexis
Market: Rheumatoid arthritis · United States
Persona: AI answers generated with a US rheumatologist persona
Open questions: 454 questions · 1,816 answers
Comparative questions: 240 questions · 960 answers
Measured: 30 October 2026
Published: 7 November 2026
AI systems: ChatGPT (GPT-5.4-mini), Claude (Claude Haiku 4.5), Gemini (Gemini 3.1 Flash-Lite), Perplexity (Sonar)
Head-to-head judge: gpt-4.1-mini

Visibility does not necessarily translate into preference.

Compare two therapies, as AI compares them.

AdalimumabvsUpadacitinib

AbataceptvsAdalimumab

AdalimumabvsUpadacitinib

AbataceptvsRituximab

AbataceptvsTocilizumab

SarilumabvsTocilizumab

AbataceptvsUpadacitinib

AdalimumabvsBaricitinib

AdalimumabvsEtanercept

AdalimumabvsTocilizumab

EtanerceptvsTofacitinib

TofacitinibvsUpadacitinib

AdalimumabvsCertolizumab pegol

AdalimumabvsSarilumab

AdalimumabvsTofacitinib

BaricitinibvsTofacitinib

BaricitinibvsUpadacitinib

AbataceptvsSarilumab

AbataceptvsTofacitinib

Certolizumab pegolvsEtanercept

EtanerceptvsTocilizumab

RituximabvsTocilizumab

RituximabvsUpadacitinib

TocilizumabvsUpadacitinib

AbataceptvsBaricitinib

AbataceptvsEtanercept

AdalimumabvsGolimumab

AdalimumabvsInfliximab

BaricitinibvsEtanercept

BaricitinibvsRituximab

BaricitinibvsSarilumab

BaricitinibvsTocilizumab

Certolizumab pegolvsUpadacitinib

EtanerceptvsUpadacitinib

GolimumabvsTocilizumab

InfliximabvsTocilizumab

LeflunomidevsMethotrexate

MethotrexatevsSulfasalazine

RituximabvsSarilumab

RituximabvsTofacitinib

SarilumabvsTofacitinib

SarilumabvsUpadacitinib

TocilizumabvsTofacitinib

Visible, first, favoured: one therapy at a time.

Abatacept

Rituximab

Tocilizumab

Tofacitinib

Adalimumab

Upadacitinib

The question changes the verdict.

What a verdict is, and what it is not.

For brand directors and medical affairs leads

Discuss your competitive AI representation

What was measured